Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

2015372 citationsJournal Articlebronze Open Access

Authors

Duncan Richards · University College London

Louise Cookson · GlaxoSmithKline (United Kingdom)

Aliénor Berges · University College London

Sharon V. Barton · GlaxoSmithKline (United Kingdom)

Thirusha Lane · The Royal Free Hospital

James M. Ritter · University College London

Marianna Fontana

Abstract

Treatment with CPHPC followed by an anti-SAP antibody safely triggered clearance of amyloid deposits from the liver and some other tissues. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01777243.).

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Drug Transport and Resistance Mechanisms Parathyroid Disorders and Treatments

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 12, pp. 1106-1114

DOI: 10.1056/nejmoa1504942

Field-Weighted Citation Impact: 23.87

Command Palette

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

Authors

Abstract

Topics & Keywords

Publication Details